Amdocs (DOX) Reports In-Line Q3 EPS, Offers Guidance

Amdocs (NASDAQ: DOX) reported Q3 EPS of $1.27, in-line with the analyst estimate of $1.27. Revenue for the quarter came in at $1.16 billion versus the consensus estimate of $1.16 billion.

GUIDANCE:

Amdocs sees Q4 2022 EPS of $1.26-$1.32, versus the consensus of $1.25. Amdocs sees Q4 2022 revenue of $1.145-1.185 billion, versus the consensus of $1.15 billion.

For earnings history and earnings-related data on Amdocs (DOX) click here.

You May Also Be Interested In

• Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
• Syra Health names Dr. Cori McMahon as fractional chief medical officer
• bioAffinity Technologies Q2 CyPath Lung sales rise over 200% year-over-year